You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Electrical System for Rapid Bacterial Cultures

    SBC: TECHSHOT, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): The broad, long-term objective of the proposed project Electrical System for Rapid Bacterial Cultures is to develop an automated electrical impedance analyzer for measuring bacterial growth in contaminated blood. Thepurpose of the System is to hasten the time to diagnose sepsis from 1-2 days down to a few hours. The specific aims of the project are to (1) bui ...

    SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  2. Rapid Response Vaccines for Botulinum Neurotoxins

    SBC: Iterative Therapeutics Inc.            Topic: NIAID

    DESCRIPTION (provided by applicant): Botulinum neurotoxins (BoNTs) are the most potent protein toxins known. Given their potent toxicity and their potential use in bio-warfare scenarios, BoNTs are included among the Category A select agents. The currentlyavailable pentavalent toxoid vaccine requires multiple boosters before being effective, and protects unequally against the different BoNT serotyp ...

    SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  3. Contrast agents for high-sensitivity ultrasound molecular imaging of tumor angiog

    SBC: TARGESON, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): Molecular imaging techniques have strong potential in the setting of preclinical research, primarily for drug discovery and basic science in the field of cancer research. In particular, high-frequency ultrasound is a powerful imaging modality for phenotyping and monitoring the response to experimental therapy. Relative to other molecular imaging techniques, ult ...

    SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  4. Multifunctional Peptides for (MRI) Imaging

    SBC: CDG THERAPEUTICS, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): Our overall goal is to expand the role of CPPs in molecular imaging at the patient level using large animal models of human tumors and a peptide agent that inherently provides 1) preferential access to a wide variety ofhuman solid (and hematologic) tumor cells, 2) an increased intracellular concentration (2-12 fold) over histologically matched normal cells, and ...

    SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  5. Developing a plectin-1 targeted imaging agent for the detection of pancreatic can

    SBC: iTi Health            Topic: NCI

    DESCRIPTION (provided by applicant): Pancreatic ductal adenocarcinoma (PDAC) is an intractable clinical problem, typically presenting with metastasis at the time of diagnosis and exhibiting profound resistance to existing therapies. Currently, the standarddiagnostic course includes CT or MRI scans which do not have optimal sensitivity and specificity for accurately diagnosing and determining resec ...

    SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  6. Intra-Oral drug-eluting adhesive film

    SBC: AKINA, INC.            Topic: NIDCR

    DESCRIPTION (provided by applicant): The objective of this Phase I study is to develop an intra-oral, adhesive film which can cover and protect various mouth sores and deliver low doses of pain relieving lidocaine and anti-inflammatory doxycycline to thesore site. In particular, we will focus on developing the adhesive film for treating canker sores, which is a ubiquitous problem affecting many p ...

    SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  7. Optimal Prevention and Control of Periodontal Disease: The Periodontal Pocket Irr

    SBC: C. PAXTON DESIGNS INC.            Topic: NIDCR

    DESCRIPTION (provided by applicant): Periodontal disease is a chronic bacterial infection that affects the gums and bone that surrounds supported teeth. According to the NIH fact sheet an estimated 80 percent of American adults have some form of periodontal disease. Gingivitis, a milder form of gum disease, is caused by plaque bio-film, which surrounds the teeth at the base of the gum line, causin ...

    SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  8. Digital image analysis for quantitative and qualitative assessment of pig islets

    SBC: VITACYTE LLC            Topic: NIDDK

    DESCRIPTION (provided by applicant): The demonstration by the Edmonton group that human islet transplantation can be successfully used to manage adult type 1 diabetes patients with refractory hypoglycemia has led to increased funding of clinical trials andfurther research to extend the scope of this therapy by using porcine islets in place of human islets. Significant advances have been made in im ...

    SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  9. Hemodynamic Co-Culture Liver Model for Drug Discovery and Assessment

    SBC: HemoShear Therapeutics, LLC            Topic: NIDDK

    DESCRIPTION (provided by applicant): Drug developers desperately need better tools in the laboratory to improve the 90% failure rate of drugs in clinical trials. Liver toxicity is still the leading cause of drug failure, despite extensive preclinical testing in surrogate animal species. HemoShear develops human surrogate technologies for target ID and validation and screening of compounds for safe ...

    SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  10. New drug Vida-5 for treating chronic kidney disease progression

    SBC: Vidasym, Inc            Topic: NIDDK

    DESCRIPTION (provided by applicant): Twenty-six million people in America have chronic kidney disease (CKD). Anemia, cardiovascular diseases, secondary hyperparathyroidism, renal osteodystrophy and other complications are common in CKD. Current treatmentsincluding ACE inhibitors for CKD patients mainly focus on managing symptoms and disease complications. Despite the various treatments available, ...

    SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government